BioHarvest Sciences Stock Drops 15% Following Announcement of $17.4 Million Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: NASDAQ.COM
Stock Performance: BioHarvest Sciences Inc. (BHST) shares fell 14.75% to $6.68 following the announcement of a public offering of 2.5 million shares priced at $7.00 each.
Funding Goals: The company aims to raise approximately $17.4 million to support various initiatives, including research and development, marketing, and debt reduction.
Offering Details: BioHarvest has granted underwriters a 30-day option to purchase an additional 372,750 shares at the offering price, with the offering expected to close around November 10, 2025.
Trading Activity: On the day of the announcement, BHST opened at $7.81, with a trading volume significantly higher than average, and its 52-week stock range is noted as $3.12 - $9.74.
Analyst Views on BHST
Wall Street analysts forecast BHST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHST is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
No data
About BHST
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
